Management of High-Risk Localized Prostate Cancer. (1st November 2011)

• Record Type: Journal Article
• Authors: Marciscano, Ariel E.; Hardee, Matthew E.; Sanfilippo, Nicholas
• Other Names: Spahn Martin Academic Editor.
• Is Part Of: Advances in urology. Volume 2012(2012)
• Publication Date: 2011-11-01
• Subjects: Urology -- Periodicals; 616.6005
• DOI: 10.1155/2012/641689
• Languages: English
• ISSNs: 1687-6369

Abstract

Abstract : Traditionally, patients with high-risk localized prostate cancer have been an extremely challenging group to manage due to a significant likelihood of treatment failure and prostate cancer-specific mortality (PCSM). The results of multiple large, prospective, randomized trials have demonstrated that men with high-risk features who are treated in a multimodal fashion at the time of initial diagnosis have improved overall survival. Advances in local treatments such as dose-escalated radiotherapy in conjunction with androgen suppression and postprostatectomy adjuvant radiotherapy have also demonstrated benefits to this subset of patients. However, therapeutic enhancement with the addition of chemotherapy to the primary treatment regimen may help achieve optimal disease control.